Effects of quadrivalent human papillomavirus vaccination

Lancet. 2007 Sep 22;370(9592):1031; author reply 1032-3. doi: 10.1016/S0140-6736(07)61470-6.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Cost-Benefit Analysis
  • Developed Countries*
  • Developing Countries*
  • Female
  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
  • Humans
  • Papillomavirus Vaccines*
  • Prevalence
  • Uterine Cervical Dysplasia / epidemiology
  • Uterine Cervical Dysplasia / pathology
  • Uterine Cervical Dysplasia / prevention & control*

Substances

  • Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18
  • Papillomavirus Vaccines